Anxiety Disorders Common, Untreated
Anxiety Disorders Common, Untreated
Study: Nearly 1 in 5 Had an Anxiety Disorder; Many Not Getting Help
Among patients with at least one anxiety disorder, 41% said they weren't getting any medication, counseling, or psychotherapy.
The anxious patients were more likely to be depressed and reported more disability days in the previous three months compared with those without anxiety disorders.
The survey may help doctors identify patients with anxiety disorder, write Kroenke and colleagues.
Identifying anxiety disorders is the first step toward getting help, note journal editorialists Wayne Katon, MD, and Peter Roy-Byrne, MD, who work in Seattle at the University of Washington's medical school.
The study has some limits. For instance, patients who declined the follow-up interview weren't included in the results. They tended to be less anxious than those who agreed to the interview.
The study was funded by the drug company Pfizer. In the journal, the researchers disclose consultancies, grants, or honoraria from the drug companies Pfizer, Eli Lilly, and Wyeth.
The editorialists note consultancies, honoraria, and grants from the drug companies Alza, Cephalon, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Jazz Pharmaceuticals, Novartis, Pfizer, Pharmacia, Roche, Solvay, Wyeth-Ayerst, and the Janssen Research Foundation.
Anxiety Disorders Common, Untreated
Study: Nearly 1 in 5 Had an Anxiety Disorder; Many Not Getting Help
Anxiety Disorders Were Common continued...
Among patients with at least one anxiety disorder, 41% said they weren't getting any medication, counseling, or psychotherapy.
The anxious patients were more likely to be depressed and reported more disability days in the previous three months compared with those without anxiety disorders.
The survey may help doctors identify patients with anxiety disorder, write Kroenke and colleagues.
Identifying anxiety disorders is the first step toward getting help, note journal editorialists Wayne Katon, MD, and Peter Roy-Byrne, MD, who work in Seattle at the University of Washington's medical school.
The study has some limits. For instance, patients who declined the follow-up interview weren't included in the results. They tended to be less anxious than those who agreed to the interview.
The study was funded by the drug company Pfizer. In the journal, the researchers disclose consultancies, grants, or honoraria from the drug companies Pfizer, Eli Lilly, and Wyeth.
The editorialists note consultancies, honoraria, and grants from the drug companies Alza, Cephalon, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Jazz Pharmaceuticals, Novartis, Pfizer, Pharmacia, Roche, Solvay, Wyeth-Ayerst, and the Janssen Research Foundation.
Source...